Qualifying Therapeutic Discovery Project Credits for the State of Massachusetts
The listings below represent the applicants that are eligible for a Qualifying Therapeutic Discovery Program Credit.
The project descriptions below were extracted from the applicant certification forms as submitted. The list provides only the applicant name and amount of the credit for each project for which the disclosure of additional information was not authorized.
|Applicant Name||Project Name||Eligible Credit Amount 2009||Eligible Credit Amount 2010|
|Alopexx Pharmaceuticals, LLC||Clinical Development of F598||$ 244,479.25|
|Concert Medical, LLC||$ 86,632.50|
|Concert Medical, LLC||$ 52,947.00|
|Levitronix LLC||LevitronixR CentriMagR VAS Failuer-to- Wean form Cardiopulmonary Bypass Trial||$ 138,531.50||$ 105,947.74|
|Nextcea, Inc||Diagnosis and Therapy of Drug-Induced Phospholipidosis and of Niemann-Pick Diseases||$ 178,372.00|
|Radiation Monitoring Device Inc A division of Dynasil Corporation of America||Practical method for Growing Scintillators for the Next Generation of SPECT Imagers||$ 244,479.25|
|Radiation Monitoring Device Inc A Divison of Dynasil Corporation of America||Optimized Proton Beam Energy For Cancer Treatment||$ 244,479.25|
|Radiation Monitoring Device, Inc - A Division of Dynasil Corporation of America||Reduced Afterglow Scintillator Films for high Speed Medical Imaging||$ 244,479.25|
|Radiation Monitoring Device, Inc. - A Div of Dynasil Corp||New Capabilities for Diffuse Optical Tomography Systems||$ 223,833.00||$ 20,646.25|
|Radiation Monitoring Device, Inc.- A Division of Dynasil Corporation of America||Ceramic Scintillator Detectors for Time of Flight PET||$ 244,479.25|
|Science Research Laboratory Inc||$ 244,479.25|
|VisionScope Technologies LLC||$ 244,479.24|